1800 OWENS STREET, SAN FRANCISCO, CA
Provides Corporate Update and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Executive Departure - Mark Eisner Steps Down as CMO of Vir Biotechnology
Marianne De Backer Appointed President of Vir Biotechnology, Inc.
Other Events
Vir Biotechnology Enters Underwriting Agreement for $141.1 Million Offering
Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager in Patients with Metastatic Prostate Cancer, Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
Investor Presentation
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
S-1MEF
Correspondence
Submission Upload